The emerging role of epigenetic mechanisms in the etiology of neural tube defects

Epigenetics

Volumn 6, Issue 7, 2011, Pages 875-883

  Greene, Nicholas D E ^a   Stanier, Philip ^a   Moore, Gudrun E ^b  

^a Neural Development Unit   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Acetylation; Chromatin; Diet; Epigenetic regulation; Epigenome; Folic acid; Histones; Methylation; Neural tube defects

Indexed keywords

5 METHYLCYTOSINE; 5 METHYLTETRAHYDROFOLIC ACID; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); COMPLEMENTARY RNA; CYANOCOBALAMIN; CYTOSINE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; FOLATE RECEPTOR 1; FOLATE RECEPTOR 2; FOLIC ACID; GENOMIC DNA; HOMOCYSTEINE; METHIONINE SYNTHASE; PYRIMIDINE; REDUCED FOLATE CARRIER; S ADENOSYLMETHIONINE; SMALL INTERFERING RNA; SPACER DNA;

ARTICLE; CATALYSIS; CHROMATIN STRUCTURE; CPG ISLAND; DNA DETERMINATION; DNA METHYLATION; DOWN REGULATION; ENZYME INHIBITION; EPIGENETICS; FOLATE METABOLISM; FOLIC ACID BLOOD LEVEL; FOLIC ACID DEFICIENCY; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC CORRELATION; GENETIC RISK; GENETIC VARIABILITY; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; LONG INTERSPERSED REPEAT; MATERNAL BLOOD; NEURAL TUBE DEFECT; NONHUMAN; NUCLEAR REPROGRAMMING; NUCLEOTIDE METABOLISM; PATHOGENESIS; PRIMORDIAL GERM CELL; TRANSCRIPTION REGULATION; TRANSPOSON; VITAMIN SUPPLEMENTATION;

EID: 79960124420     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.6.7.16400     Document Type: Article

References (114)

1. Copp AJ, Greene NDE, Murdoch JN. The genetic basis of mammalian neurulation. Nat Rev Genet 2003; 4:784-793.
2. Greene ND, Copp AJ. Development of the vertebrate central nervous system: formation of the neural tube. Prenatal Diag 2009; 29:303-311.
3. Moore CA. Classification of neural tube defects. In: Wyszynski DF, Ed. Neural Tube Defects: From Origin to Treatment. Oxford: Oxford University Press 2006; 66-75.
4. Copp AJ, Greene NDE. Genetics and development of neural tube defects. J Pathol 2010; 220:217-230.
5. Copp AJ. Neurulation in the cranial region-normal and abnormal. J Anat 2005; 207:623-635.
6. Mitchell LE. Epidemiology of neural tube defects. Am J Med Genet C Semin Med Genet 2005; 135:88-94.
7. Holmes LB, Driscoll SG, Atkins L. Etiologic heterogeneity of neural-tube defects. N Engl J Med 1976; 294:365-369.
8. Detrait ER, George TM, Etchevers HC, Gilbert JR, Vekemans M, Speer MC. Human neural tube defects: developmental biology, epidemiology and genetics. Neurotoxicol Teratol 2005; 27:515-524.
9. Greene NDE, Stanier P, Copp AJ. Genetics of human neural tube defects. Hum Mol Gene 2009; 18:113-129.
10. Kennedy D, Chitayat D, Winsor EJT, Silver M, Toi A. Prenatally diagnosed neural tube defects: Ultrasound, chromosome and autopsy or postnatal findings in 212 cases. Am J Med Genet 1998; 77:317-321.
11. Chen CP. Chromosomal abnormalities associated with neural tube defects (I): full aneuploidy. Taiwan J Obstet Gynecol 2007; 46:325-335.
12. Chen CP. Chromosomal abnormalities associated with neural tube defects (II): partial aneuploidy. Taiwan J Obstet Gynecol 2007; 46:336-351.
13. Harris MJ, Juriloff DM. An update to the list of mouse mutants with neural tube closure defects and advances toward a complete genetic perspective of neural tube closure. Birth Defects Res A Clin Mol Teratol 2010; 88:653-669.
14. Harris MJ, Juriloff DM. Mouse mutants with neural tube closure defects and their role in understanding human neural tube defects. Birth Defects Res A Clin Mol Teratol 2007; 79:187-210.
15. Brouns MR, De Castro SC, Terwindt-Rouwenhorst EA, Massa V, Hekking JW, Hirst CS, et al. Overexpression of Grhl2 causes spina bifida in the Axial defects mutant mouse. Hum Mol Genet 2011; 20:1536-1546.
16. Eriksson UJ, Cederberg J, Wentzel P. Congenital malformations in offspring of diabetic mothers-animal and human studies. Rev Endocr Metab Disord 2003; 4:79-93.
17. Hendricks KA, Nuno OM, Suarez L, Larsen R. Effects of hyperinsulinemia and obesity on risk of neural tube defects among Mexican Americans. Epidemiology 2001; 12:630-635.
18. Suarez L, Ramadhani T, Felkner M, Canfield MA, Brender JD, Romitti PA, et al. Maternal smoking, passive tobacco smoke and neural tube defects. Birth Defects Res A Clin Mol Teratol 2011; 91:29-33.
19. Marasas WF, Riley RT, Hendricks KA, Stevens VL, Sadler TW, Gelineau-van Waes J, et al. Fumonisins disrupt sphingolipid metabolism, folate transport and neural tube development in embryo culture and in vivo: a potential risk factor for human neural tube defects among populations consuming fumonisincontaminated maize. J Nutr 2004; 134:711-716.
20. Buehler BA, Rao V, Finnell RH. Biochemical and molecular teratology of fetal hydantoin syndrome. Neurol Clin 1994; 12:741-748.
21. Yazdy MM, Liu S, Mitchell AA, Werler MM. Maternal dietary glycemic intake and the risk of neural tube defects. Am J Epidemiol 2009; 171:407-414.
22. Smithells RW, Sheppard S, Schorah CJ. Vitamin deficiencies and neural tube defects. Arch Dis Child 1976; 51:944-950.
23. Kirke PN, Molloy AM, Daly LE, Burke H, Weir DG, Scott JM. Maternal plasma folate and vitamin B12 are independent risk factors for neural tube defects. Q J Med 1993; 86:703-708.
24. Smithells RW, Sheppard S, Schorah CJ, Seller MJ, Nevin NC, Harris R, et al. Possible prevention of neural-tube defects by periconceptional vitamin supplementation. Lancet 1980; 1:339-340.
25. Wald N, Sneddon J, Densem J, Frost C, Stone R. MRC Vitamin Study Res Group. Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study. Lancet 1991; 338:131-137.
26. Czeizel AE, Dudás I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327:1832-1835.
27. Waterland RA, Michels KB. Epigenetic epidemiology of the developmental origins hypothesis. Annu Rev Nutr 2007; 27:363-388.
28. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010; 31:27-36.
29. Burdge GC, Lillycrop KA. Nutrition, epigenetics and developmental plasticity: implications for understanding human disease. Annu Rev Nutr 2010; 30:315-339.
30. Vaissiere T, Sawan C, Herceg Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res 2008; 659:40-48.
31. Clouaire T, Stancheva I. Methyl-CpG binding proteins: specialized transcriptional repressors or structural components of chromatin? Cell Mol Life Sci 2008; 65:1509-1522.
32. Whitelaw NC, Whitelaw E. How lifetimes shape epigenotype within and across generations. Hum Mol Genet 2006; 15:131-137.
33. Guil S, Esteller M. DNA methylomes, histone codes and miRNAs: tying it all together. Int J Biochem Cell Biol 2009; 41:87-95.
34. Zeisel SH. Epigenetic mechanisms for nutrition determinants of later health outcomes. Am J Clin Nutr 2009; 89:1488-1493.
35. Kim JK, Samaranayake M, Pradhan S. Epigenetic mechanisms in mammals. Cell Mol Life Sci 2009; 66:596-612.
36. Delcuve GP, Rastegar M, Davie JR. Epigenetic control. J Cell Physiol 2009; 219:243-250.
37. Morgan HD, Santos F, Green K, Dean W, Reik W. Epigenetic reprogramming in mammals. Hum Mol Genet 2005; 14:47-58.
38. Kelly TL, Trasler JM. Reproductive epigenetics. Clin Genet 2004; 65:247-260.
39. Junien C, Nathanielsz P. Report on the IASO Stock Conference 2006: early and lifelong environmental epigenomic programming of metabolic syndrome, obesity and type II diabetes. Obes Rev 2007; 8:487-502.
40. Jones PA, Liang G. Rethinking how DNA methylation patterns are maintained. Nat Rev Genet 2009; 10:805-811.
41. Bird A. Perceptions of epigenetics. Nature 2007; 447:396-398.
42. Métivier R, Gallais R, Tiffoche C, Le Péron C, Jurkowska RZ, Carmouche RP, et al. Cyclical DNA methylation of a transcriptionally active promoter. Nature 2008; 452:45-50.
43. Popp C, Dean W, Feng S, Cokus SJ, Andrews S, Pellegrini M, et al. Genome-wide erasure of DNA methylation in mouse primordial germ cells is affected by AID deficiency. Nature 2010; 463:1101-1105.
44. Steegers-Theunissen RP, Boers GH, Trijbels FJ, Finkelstein JD, Blom HJ, Thomas CM, et al. Maternal hyperhomocysteinemia: A risk factor for neural tube defects. Metabolism 1994; 43:1475-1480.
45. Mills JL, McPartlin JM, Kirke PN, Lee YJ, Conley MR, Weir DG, et al. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 1995; 345:149-151.
46. Ray JG, Wyatt PR, Thompson MD, Vermeulen MJ, Meier C, Wong PY, et al. Vitamin B12 and the risk of neural tube defects in a folic-acid-fortified population. Epidemiology 2007; 18:362-366.
47. Molloy AM, Brody LC, Mills JL, Scott JM, Kirke PN. The search for genetic polymorphisms in the homocysteine/folate pathway that contribute to the etiology of human neural tube defects. Birth Defects Res A Clin Mol Teratol 2009; 85:285-294.
48. van der Put NM, Steegers-Theunissen RP, Frosst P, Trijbels FJ, Eskes TK, van den Heuvel LP, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995; 346:1070-1071.
49. Shaw GM, Carmichael SL, Yang W, Selvin S, Schaffer DM. Periconceptional dietary intake of choline and betaine and neural tube defects in offspring. Am J Epidemiol 2004; 160:102-109.
50. Shaw GM, Finnell RH, Blom HJ, Carmichael SL, Vollset SE, Yang W, et al. Choline and risk of neural tube defects in a folate-fortified population. Epidemiology 2009; 20:714-719.
51. Fisher MC, Zeisel SH, Mar MH, Sadler TW. Perturbations in choline metabolism cause neural tube defects in mouse embryos in vitro. FASEB J 2002; 16:619-621.
52. Niculescu MD, Craciunescu CN, Zeisel SH. Dietary choline deficiency alters global and gene-specific DNA methylation in the developing hippocampus of mouse fetal brains. FASEB J 2006; 20:43-49.
53. Mehedint MG, Niculescu MD, Craciunescu CN, Zeisel SH. Choline deficiency alters global histone methylation and epigenetic marking at the Re1 site of the calbindin 1 gene. FASEB J 2010; 24:184-195.
54. Blom HJ, Shaw GM, Den Heijer M, Finnell RH. Neural tube defects and folate: case far from closed. Nat Rev Neurosci 2006; 7:724-731.
55. Beaudin AE, Stover PJ. Insights into metabolic mechanisms underlying folate-responsive neural tube defects: A minireview. Birth Defects Res A Clin Mol Teratol 2009; 85:274-284.
56. Greene ND, Massa V, Copp AJ. Understanding the causes and prevention of neural tube defects: Insights from the splotch mouse model. Birth Defects Res A Clin Mol Teratol 2009; 85:322-330.
57. Scott JM. Folate and vitamin B12. Proc Nutr Soc 1999; 58:441-448.
58. Burren KA, Savery D, Massa V, Kok RM, Scott JM, Blom HJ, et al. Gene-environment interactions in the causation of neural tube defects: folate deficiency increases susceptibility conferred by loss of Pax3 function. Hum Mol Genet 2008; 17:3675-3685.
59. Piedrahita JA, Oetama B, Bennett GD, van Waes J, Kamen BA, Richardson J, et al. Mice lacking the folic acid-binding protein Folbp1 are defective in early embryonic development. Nature Genet 1999; 23:228-232.
60. Spiegelstein O, Mitchell LE, Merriweather MY, Wicker NJ, Zhang Q, Lammer EJ, et al. Embryonic development of folate binding protein-1 (Folbp1) knockout mice: Effects of the chemical form, dose and timing of maternal folate supplementation. Dev Dyn 2004; 231:221-231.
61. Dunlevy LP, Chitty LS, Burren KA, Doudney K, Stojilkovic-Mikic T, Stanier P, et al. Abnormal folate metabolism in foetuses affected by neural tube defects. Brain 2007; 130:1043-1049.
62. Fleming A, Copp AJ. Embryonic folate metabolism and mouse neural tube defects. Science 1998; 280:2107-2109.
63. Beaudin AE, Abarinov EV, Noden DM, Perry CA, Chu S, Stabler SP, et al. Shmt1 and de novo thymidylate biosynthesis underlie folate-responsive neural tube defects in mice. Am J Clin Nutr 2011; 93:789-798.
64. Scott JM, Weir DG, Molloy A, McPartlin J, Daly L, Kirke P. Folic acid metabolism and mechanisms of neural tube defects. In: Bock G, Marsh J, Eds. Neural Tube Defects (Ciba Foundation Symposium 181). Chichester: John Wiley & Sons 1994; 180-187.
65. Finnell RH, Blom HJ, Shaw GM. Does global hypomethylation contribute to susceptibility to neural tube defects? Am J Clin Nutr 2010; 91:1153-1154.
66. Fryer AA, Nafee TM, Ismail KM, Carroll WD, Emes RD, Farrell WE. LINE-1 DNA methylation is inversely correlated with cord plasma homocysteine in man: a preliminary study. Epigenetics 2009; 4:394-398.
67. Fryer AA, Emes RD, Ismail KM, Haworth KE, Mein C, Carroll WD, et al. Quantitative, high-resolution epigenetic profiling of CpG loci identifies associations with cord blood plasma homocysteine and birth weight in humans. Epigenetics 2011; 6:86-94.
68. Wang L, Wang F, Guan J, Le J, Wu L, Zou J, et al. Relation between hypomethylation of long interspersed nucleotide elements and risk of neural tube defects. Am J Clin Nutr 2010; 91:1359-1367.
69. Chang H, Zhang T, Zhang Z, Bao R, Fu C, Wang Z, et al. Tissue-specific distribution of aberrant DNA methylation associated with maternal low-folate status in human neural tube defects. J Nutr Biochem 2011; In press.
70. Okano M, Bell DW, Haber DA, Li E. DNA m ethyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999; 99:247-257.
71. Matsuda M. Comparison of the incidence of 5-azacytidine- induced exencephaly between MT/HokIdr and Slc:ICR mice. Teratology 1990; 41:147-154.
72. Dunlevy LPE, Burren KA, Chitty LS, Copp AJ, Greene NDE. Excess methionine suppresses the methylation cycle and inhibits neural tube closure in mouse embryos. FEBS Lett 2006; 580:2803-2807.
73. Dunlevy LPE, Burren KA, Mills K, Chitty LS, Copp AJ, Greene NDE. Integrity of the methylation cycle is essential for mammalian neural tube closure. Birth Defects Res A 2006; 76:544-552.
74. Chen Z, Karaplis AC, Ackerman SL, Pogribny IP, Melnyk S, Lussier-Cacan S, et al. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet 2001; 10:433-443.
75. Elmore CL, Wu X, Leclerc D, Watson ED, Bottiglieri T, Krupenko NI, et al. Metabolic derangement of methionine and folate metabolism in mice deficient in methionine synthase reductase. Mol Genet Metab 2007; 91:85-97.
76. van der Linden IJ, den Heijer M, Afman LA, Gellekink H, Vermeulen SH, Kluijtmans LA, et al. The methionine synthase reductase 66A>G polymorphism is a maternal risk factor for spina bifida. J Mol Med 2006; 84:1047-1054.
77. Greene NDE, Dunlevy LE, Copp AJ. Homocysteine is embryotoxic but does not cause neural tube defects in mouse embryos. Anat Embryol 2003; 206:185-191.
78. Bennett GD, Vanwaes J, Moser K, Chaudoin T, Starr L, Rosenquist TH. Failure of homocysteine to induce neural tube defects in a mouse model. Birth Defects Res B Dev Reprod Toxicol 2006; 77:89-94.
79. Iskandar BJ, Rizk E, Meier B, Hariharan N, Bottiglieri T, Finnell RH, et al. Folate regulation of axonal regeneration in the rodent central nervous system through DNA methylation. J Clin Invest 2010; 120:1603-1616.
80. Waterland RA, Jirtle RL. Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol Cell Biol 2003; 23:5293-5300.
81. Burgoon JM, Selhub J, Nadeau M, Sadler TW. Investigation of the effects of folate deficiency on embryonic development through the establishment of a folate deficient mouse model. Teratology 2002; 65:219-227.
82. Pickell L, Li D, Brown K, Mikael LG, Wang XL, Wu Q, et al. Methylenetetrahydrofolate reductase deficiency and low dietary folate increase embryonic delay and placental abnormalities in mice. Birth Defects Res A Clin Mol Teratol 2009; 85:531-541.
83. Burren KA, Scott JM, Copp AJ, Greene ND. The genetic background of the curly tail strain confers susceptibility to folate-deficiency-induced exencephaly. Birth Defects Res A Clin Mol Teratol 2010; 88:76-83.
84. De Castro SC, Leung KY, Savery D, Burren K, Rozen R, Copp AJ, et al. Neural tube defects induced by folate deficiency in mutant curly tail (Grhl3) embryos are associated with alteration in folate onecarbon metabolism but are unlikely to result from diminished methylation. Birth Defects Res A Clin Mol Teratol 2010; 88:612-618.
85. Ichi S, Costa FF, Bischof JM, Nakazaki H, Shen YW, Boshnjaku V, et al. Folic acid remodels chromatin on Hes1 and Neurog2 promoters during caudal neural tube development. J Biol Chem 2010; 285:36922-36932.
86. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol 2010; 28:1057-1068.
87. Yao TP, Oh SP, Fuchs M, Zhou ND, Ch'ng LE, Newsome D, et al. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 1998; 93:361-72.
88. Ruthenburg AJ, Li H, Patel DJ, Allis CD. Multivalent engagement of chromatin modifications by linked binding modules. Nat Rev Mol Cell Biol 2007; 8:983-994.
89. Bu P, Evrard YA, Lozano G, Dent SY. Loss of Gcn5 acetyltransferase activity leads to neural tube closure defects and exencephaly in mouse embryos. Mol Cell Biol 2007; 27:3405-3416.
90. Lin W, Zhang Z, Srajer G, Chen YC, Huang M, Phan HM, et al. Proper expression of the Gcn5 histone acetyltransferase is required for neural tube closure in mouse embryos. Dev Dyn 2008; 237:928-940.
91. Dunwoodie SL, Rodriguez TA, Beddington RSP. Msg1 and Mrg1, founding members of a gene family, show distinct patterns of gene expression during mouse embryogenesis. Mech Dev 1998; 72:27-40.
92. Bhattacharya S, Michels CL, Leung MK, Arany ZP, Kung AL, Livingston DM. Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. Genes Dev 1999; 13:64-75.
93. Yin Z, Haynie J, Yang X, Han B, Kiatchoosakun S, Restivo J, et al. The essential role of Cited2, a negative regulator for HIF-1α, in heart development and neurulation. Proc Natl Acad Sci USA 2002; 99:10488-10493.
94. Barbera JP, Rodriguez TA, Greene ND, Weninger WJ, Simeone A, Copp AJ, et al. Folic acid prevents exencephaly in Cited2 deficient mice. Hum Mol Genet 2002; 11:283-293.
95. Finnell RH, Waes JGV, Eudy JD, Rosenquist TH. Molecular basis of environmentally induced birth defects. Annu Rev Pharmacol Toxicol 2002; 42:181-208.
96. Menegola E, Di Renzo F, Broccia ML, Prudenziati M, Minucci S, Massa V, et al. Inhibition of histone deacetylase activity on specific embryonic tissues as a new mechanism for teratogenicity. Birth Defects Res B Dev Reprod Toxicol 2005; 74:392-398.
97. Massa V, Cabrera RM, Menegola E, Giavini E, Finnell RH. Valproic acid-induced skeletal malformations: associated gene expression cascades. Pharmacogenet Genomics 2005; 15:787-800.
98. Okada A, Kushima K, Aoki Y, Bialer M, Fujiwara M. Identification of early-responsive genes correlated to valproic acid-induced neural tube defects in mice. Birth Defects Res A Clin Mol Teratol 2005; 73:229-238.
99. Eikel D, Lampen A, Nau H. Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives. Chem Res Toxicol 2006; 19:272-278.
100. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 2002; 21:2672-2681.
101. Montgomery RL, Hsieh J, Barbosa AC, Richardson JA, Olson EN. Histone deacetylases 1 and 2 control the progression of neural precursors to neurons during brain development. Proc Natl Acad Sci USA 2009; 106:7876-7881.
102. Vega RB, Matsuda K, Oh J, Barbosa AC, Yang X, Meadows E, et al. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 2004; 119:555-566.
103. Cheng HL, Mostoslavsky R, Saito S, Manis JP, Gu Y, Patel P, et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci USA 2003; 100:10794-10799.
104. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005; 363:15-23.
105. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6:38-51.
106. Kim JH, Saraf A, Florens L, Washburn M, Workman JL. Gcn5 regulates the dissociation of SWI/SNF from chromatin by acetylation of Swi2/Snf2. Genes Dev 2010; 24:2766-2771.
107. Portoso M, Cavalli G, The role of RNAi and noncoding RNAs in Polycomb mediated control of gene expression and genomic programming. In: Morris K, Ed. RNA and the regulation of gene expression: a hidden layer of complexity. Caister Academic Press 2088:29-44.
108. Schones DE, Cui K, Cuddapah S, Roh TY, Barski A, Wang Z, et al. Dynamic regulation of nucleosome positioning in the human genome. Cell 2008; 132:887-898.
109. Bultman S, Gebuhr T, Yee D, La Mantia C, Nicholson J, Gilliam A, et al. A Brg1 null mutation in the mouse reveals functional differences among mammalian SWI/SNF complexes. Mol Cell 2000; 1287-1295.
110. Banting GS, Barak O, Ames TM, Burnham AC, Kardel MD, Cooch NS, et al. CECR2, a protein involved in neurulation, forms a novel chromatin remodeling complex with SNF2L. Hum Mol Genet 2005; 14:513-524.
111. Kim JK, Huh SO, Choi H, Lee KS, Shin D, Lee C, et al. Srg3, a mouse homolog of yeast SWI3, is essential for early embryogenesis and involved in brain development. Mol Cell Biol 2001; 21:7787-7795.
112. Gyuris A, Donovan DJ, Seymour KA, Lovasco LA, Smilowitz NR, Halperin AL, et al. The chromatin targeting protein Brd2 is required for neural tube closure and embryogenesis. Biochim Biophys Acta 2009; 1789:413-421.
113. Euskirchen GM, Auerbach RK, Davidov E, Gianoulis TA, Zhong G, Rozowsky J, et al. Diverse roles and interactions of the SWI/SNF chromatin remodeling complex revealed using global approaches. PLoS Genet 2011; 7:1002008.
114. Wu M, Zhang Y, Wu NH, Shen YF. Histone marks and chromatin remodelers on the regulation of neurogenin1 gene in RA induced neuronal differentiation of P19 cells. J Cell Biochem 2009; 107:264-271.